衛生福利部與經濟部於11月18日在國家生技研究園區共同舉辦「2025國家藥物科技研究發展獎」頒獎典禮，長聖生技的「CAR001-異體移植mRNA基因轉殖的多靶向CAR-γδ T細胞治療實體腫瘤」榮獲藥品類-銅質獎，針對異體、非病毒mRNA編輯的多靶點免疫細胞療法，專為難治型實體腫瘤設計，如大腸直腸癌、三陰性乳癌、膠質母細胞瘤及非小細胞肺癌等，在研發領域中的卓越成就受到評審們的肯定，期望透過各單位的持續支持與推動，攜手共創生技醫藥品牌的新價值，朝向為國人帶來更健康的目標穩健邁進。
On November 18th, the Ministry of Health and Welfare and the Ministry of Economic Affairs jointly held the "2025 National Pharmaceutical Technology Research and Development Award" ceremony at the National Biotechnology Research Park. Ever-Supreme's "CAR001-Allogeneic mRNA Gene Transplantation Multi-Targeted CAR-γδ T Cell Therapy for Solid Tumors" won the Bronze Award in the Pharmaceutical Category. This multi-target immunotherapy, which targets allogeneic, non-viral mRNA editing, is specifically designed for refractory solid tumors such as colorectal cancer, triple-negative breast cancer, glioblastoma, and non-small cell lung cancer. Its outstanding achievements in the research and development field were recognized by the judges. It is hoped that with the continued support and promotion of various units, they can work together to create new value for biotechnology and pharmaceutical brands and steadily move towards the goal of bringing better health to the people of Taiwan.
